FIELD : medicine.SUBSTANCE : invention relates to medicine, namely to therapy and endocrinology, and can be used to treat diabetic foot syndrome. For this purpose, a biomedical cell product is introduced, the cell line comprising which has a CD marker selected from the group consisting of CD73, CD106, CD146, CD200, CD271, and the cells as part of which are administered in a dose of 10 to 50 thousand skin cells/cm2.EFFECT : method allows to increase the effectiveness of treatment of diabetic foot syndrome when using low doses of cells due to their accurate marker verification.3 cl, 3 dwg, 1 tbl, 6 ex